Get started
Author

Jennifer L. Quizi

Observed names: J L Quizi, J. Quizi, Jennifer Quizi
OpenAlex ID: A5044307129
Focal adhesion kinase inhibitors are potent anti‐angiogenic agents
2011 · Miguel A. Cabrita, Laura M. Jones, et al. · Molecular Oncology · 85
PDF
SLK-mediated phosphorylation of paxillin is required for focal adhesion turnover and cell migration
2012 · J L Quizi, K Baron, et al. · Oncogene · 50
PDF
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies
2022 · Natasha Kekre, Kevin A. Hay, et al. · Frontiers in Immunology · 31
Essential role for the SLK protein kinase in embryogenesis and placental tissue development
2013 · Khalid N. Al‐Zahrani, Prabhjot Sekhon, et al. · Developmental Dynamics · 18
Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies
2022 · Donald J. Bastin, Jennifer Quizi, et al. · Cytotherapy · 7
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors
2026 · Franz J. Zemp, Zackariah Breckenridge, et al. · Nature Cancer · 3
Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB
2025 · Franz J. Zemp, Zackariah Breckenridge, et al. · medRxiv · 3
From classroom to cleanroom: building a skilled cell and gene therapy workforce
2026 · Ali Shokoohmand, Eddie H.P. Tan, et al. · Cytotherapy · 1
PDF
Establishing AAV GMP Production Capacity to Accelerate Development of Novel Gene Therapies
2025 · P. Yoganathan, J. Quizi · Cytotherapy · 1
PA-144 Development of BCMA-Specific TAC-T Cells: Enabling TACtful, a First-in-Human Study in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
2026 · Laura Pearce, Joanne A. Hammill, et al. · Clinical Lymphoma Myeloma & Leukemia
De-risking Aav Gene Therapy Manufacturing Through Platform Process Design
2026 · P. Yoganathan, J. Laframboise, et al. · Cytotherapy
Works count: 11
Citation count: 199
H-index: 5
I10-index: 4
Year
Topic
Type